Zhang Ye, Huang Longchang, Shi Haoze, Chen Hang, Tao Jianxin, Shen Renhui, Wang Tong
Department of Endoscopy Surgery, Wuxi People's Hospital, Affiliated to Nanjing Medical University, Wuxi, China.
Cancer Sci. 2018 Jan;109(1):94-102. doi: 10.1111/cas.13425. Epub 2017 Nov 18.
It has been reported that ursolic acid has anti-tumor activity and it enhances the therapeutic effect of oxaliplatin in colorectal cancer (CRC). However, the underlying mechanisms remain unknown. In the present study, the mechanisms of the enhancement of therapeutic effects through use of ursolic acid were investigated. We treated CRC cell lines HCT8 and SW480 with ursolic acid and oxaliplatin and monitored the effects on cell proliferation, apoptosis, reactive oxygen species (ROS) production and drug resistance gene production. We discovered that treatment with a combination of ursolic acid and oxaliplatin resulted in significant inhibition of cell proliferation, significantly increased apoptosis and ROS production, and significant inhibition of drug resistance gene expression. Our study provided evidence that ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by ROS-mediated inhibition of drug resistance.
据报道,熊果酸具有抗肿瘤活性,并且能增强奥沙利铂对结直肠癌(CRC)的治疗效果。然而,其潜在机制仍不清楚。在本研究中,我们对通过使用熊果酸增强治疗效果的机制进行了研究。我们用熊果酸和奥沙利铂处理结直肠癌细胞系HCT8和SW480,并监测其对细胞增殖、凋亡、活性氧(ROS)生成和耐药基因产生的影响。我们发现,熊果酸和奥沙利铂联合处理可显著抑制细胞增殖,显著增加凋亡和ROS生成,并显著抑制耐药基因表达。我们的研究提供了证据,证明熊果酸通过ROS介导的耐药抑制作用增强了奥沙利铂对结直肠癌的治疗效果。